Richard Simcock

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

COVID-19: Global radiation oncology’s targeted response for pandemic preparedness

Richard Simcock, Toms Vengaloor Thomas, Christopher Estes et al. · Clinical and Translational Radiation Oncology · 2020 · 240 citations · Full text

ARIX: A randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer

Richard Simcock, Lesley Fallowfield, Kathryn Monson et al. · Annals of Oncology · 2012 · 104 citations · Full text

Neck Cancer, Health Sciences, Medicine +11

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · Journal of Clinical Oncology · 2018 · 70 citations

Breast Oncology, Clinical Endpoint, Population Health Sciences +16

Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer

Nicolò Matteo Luca Battisti, Malcolm Reed, Esther Herbert et al. · European Journal of Cancer · 2020 · 65 citations · Full text